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Autologous haematopoietic cell transplantation in multiple sclerosis 
Abstract 
Introduction: Autologous haematopoietic cell transplantation (AHCT) is an evolving 
treatment avenue in multiple sclerosis (MS), which may be highly effective in controlling 
disease activity and improving disability. However, AHCT is associated with intrinsic 
toxicities and risks compared with conventional therapies. With growing experience in 
patient selection and treatment delivery, AHCT is increasingly considered an option in 
patients with aggressive disease responding poorly to disease modifying therapy.   
Areas Covered: The introduction and development of AHCT as a treatment for MS over the 
last 20 years, potential mechanisms of action, patient selection, and future trends for this 
treatment approach. 
Expert Opinion: AHCT represents an extremely efficacious treatment for inflammatory 
phase MS. Currently published data suggest that its use is associated with significant 
reduction in disease activity and marked improvement in disability when used in patients 
with highly active relapsing remitting disease. Its long term safety and efficacy have not been 
fully evaluated but as increasing clinical trial data are published, its use is likely to grow. 
Further randomised controlled studies are needed to compare AHCT with standard disease 
modifying therapies and to optimise transplant regimens. Mechanistic studies may provide 
potential markers for response and a better understanding of disease pathogenesis.  
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Abbreviations 
rATG   Rabbit Anti-Thymocyte Globulin    
AHCT  Autologous Hematopoietic Cell Transplantation 
BEAM  BCNU, Ara-C, etoposide and melphalan 
BuCy  Busulfan, cyclophosphamide, and rabbit ATG 
CNS  Central Nervous System 
EBV-PTLD  Epstein-Barr Virus related post-transplant lymphoproliferative disorder 
EBMT  European Society for Blood and Marrow Transplantation 
EDSS  Expanded Disability Status Scale 
G-CSF  Granulocyte-colony stimulating factor  
MSC  Mesenchymal stem (or stromal) cell 
MRI  Magnetic resonance imaging 
MS  Multiple sclerosis 
NEDA  No evidence of disease activity 
PPMS  Primary progressive multiple sclerosis 
RRMS  Relapsing remitting multiple sclerosis 
SPMS  Secondary progressive multiple sclerosis 
TBI  Total body irradiation 
TRM  Treatment related mortality 
1.1 Introduction 
Multiple Sclerosis (MS) is an autoimmune disease that affects the central nervous system 
(CNS). It has a prevalence of 203.4 per 100 000 population in the UK [1].  Its incidence 
increases with increasing latitude, it is more common in women and it usually presents 
between the ages of 20 and 40 [2]. The classical pathological hallmarks are plaques of 
demyelination associated with inflammation and axonal transection, which develop anywhere 
within the CNS and the optic nerves. The disease has a very variable course making its 
symptoms and signs very heterogeneous.  
The clinical course of MS was traditionally categorised into three main subtypes: primary 
progressive (PPMS) where patients develop gradually worsening neurological disability with 
no relapses, relapsing remitting (RRMS), where patients develop relapses with complete or 
partial recovery followed by periods of stability, and secondary progressive (SPMS) where 
patients start with a relapsing and remitting course which culminates in periods of 
progressive accumulation of disability with or without superimposed relapses.  
More recently the clinical course of MS has been redefined based on disease activity and 
progression into a relapsing (which accounts for the RRMS) and progressive (which accounts 
for both PPMS and SPMS) phases [3] see figure 1.  
The two clinical courses of the disease probably have different pathogenic mechanisms. 
RRMS symptoms are driven by an inflammatory process within the nervous system, whereas 
in PPMS and SPMS inflammation is less evident and axonal degeneration is thought to be the 
main driver of disability progression. This is evidenced by the fact that both PPMS and 
SPMS do not readily respond to the same immunosuppressive treatments as RRMS.  
The physical impact of MS on affected patients results in disability which is traditionally 
measured using the Kurtzke Expanded Disability Status Scale or (EDSS) [4] (Table 1). This 
is an ordinal scale which combines the findings of the QHXURORJLFDOH[DPLQDWLRQDQGSDWLHQWV¶
ambulation in a single score between 0 (normal) and 10 (dead due to MS). Along with 
annualized relapse rate and MRI disease activity, the EDSS is frequently used in clinical 
WULDOVDVDSULPDU\RXWFRPHPHDVXUH0RUHUHFHQWO\WKHFRQFHSWRIµQRHYLGHQFHRIGLVHDVH
activity (NEDA), characterised by the absence of clinical relapses, disability progression and 
MRI disease activity, has been suggested as an ultimate goal of treatment response. 
Over the last 30 years, the main focus of therapeutic interventions in RRMS has been to 
modulate the immune system to stop the inflammatory process which causes the neuronal 
damage and subsequent disability. Currently available disease modifying therapies used in 
RRMS do, to varying degrees, reduce relapse rate and slow down the accumulation of 
disability, but they cannot halt its progression. There are currently no licensed treatments for 
the progressive forms of MS. 
Based on animal models and serendipitous case reports, Autologous Hematopoietic Cell 
Transplantation (AHCT) has been a used as treatment for MS for over two decades. The 
treatment was used initially in patients with advanced progressive disease as a rescue therapy 
to try and halt disease progression. Limited efficacy was seen in this group of patients.  More 
recently its use in patients with active RRMS has been associated with prolonged clinical and 
MRI responses, and, in some cases, an improvement in disability to a degree rarely seen with 
other treatments. 
In this paper we will review the development AHCT as a treatment for MS, its mechanism of 
DFWLRQSDWLHQWV¶VHOHFWLRQWUHDWPHQWUHJLPHQVDQGWKHLUVDIHW\SURILOHV:HZLOOFRPSDUHWKH
efficacy of AHCT to standard disease modifying therapies used mainly in RRMS, as this is 
where the more up to date research is focused, and comments of the future of this testament 
within the therapeutic algorithm. 
2.1 History of AHCT in MS  
The rationale for using AHCT as a treatment MS came from the observation that remission of 
co-existing severe autoimmune diseases occurred when using AHCT for the treatment of 
haematological malignancies [5].  As well as achieving remission, AHCT was shown to 
improve the symptoms of MS when used to treat haematological malignancies in patients 
with MS [6]. Rodent models of MS, specifically Experimental Autoimmune 
Encephalomyelitis, also showed that the disease could be arrested with AHCT [7], although 
caution in interpreting these results was needed due to the limitations of animal models. The 
first reported patients with MS treated with AHCT were in Thessaloniki in 1995 [8]. Since 
then, the European Society for Blood and Marrow Transplantation (EBMT) registry has over 
800 patients for MS (personal communication, EBMT Registry) [9].  
Initially, the majority of the patients treated had secondary progressive MS [8;10]. This early 
experience showed that, although AHCT seemed to reduce gadolinium enhancement in brain 
05,LPDJLQJLWGLGQRWSUHYHQWSURJUHVVLRQRIWKHGLVHDVHRULPSURYHSDWLHQWV¶RXWFRPH
[11;12].  With increasing experience, patients with RRMS were increasingly treated and 
noted to have a more favourable response, with reduction in clinical relapses, MRI disease 
activity and disability progression. In some patients an improvement in the EDSS score was 
also noted [13].  
In addition, increasing experience has led to significant modification of the conditioning 
regimens. Initially, several regimens included the use of total body irradiation (TBI) [10] and 
Busulfan [11;14;15]. These regimens were associated with high morbidity and mortality 
[14;16]. TBI was postulated to accelerate progression of disability in patients with secondary 
and primary progressive forms of MS as a result of the radiation induced axonal damage [17]. 
A meta-analysis of AHCT regimens classed as high intensity (containing TBI and Busulfan) 
or medium intensity (mainly containing BEAM [BCNU, Ara-C, etoposide and melphalan]) 
showed the use of TBI was associated with a lower progression free survival [18].  
BEAM +ATG and cyclophosphamide 200 mg/kg + ATG regimens were used from an early 
stage in MS treatment. Their acceptable safety profile has led to their continued use in recent 
clinical trials involving patients with highly active RRMS.  These regimens are both 
recommended in the current guidelines of the EBMT Autoimmune Diseases Working Party 
(ADWP) guidelines [19]. A recent study has shown that using a conditioning regimen of 
busulfan, cyclophosphamide, and rabbit ATG (BuCy) with CD34+ cell selection caused 
complete suppression of disease with no relapses for up to 5 years post-transplant in all 
patients [20]. However, there was additional toxicity with this regimen, especially hepatic 
veno-occlusive disease, a serious complication associated with busulfan treatment, which was 
associated with one treatment related mortality out of the 24 patients studied. Retrospective 
registry data suggest that purging the graft off CD34+ cells has no added benefit to the 
transplant process, and is associated with a higher treatment related mortality [16]. 
Conditioning regimens still vary between treatment centres with no standardised regimen 
adopted as yet. As the intensity of a regimen increases so does the risk of side effects and 
potential treatment related mortality (TRM) [20]. The counter argument to lower intensity 
regimens is that they are less effective in suppressing disease activity resulting in increased 
rates of relapse and disease progression [21]. 
The most appropriate conditioning regimen to use in AHCT remains an unanswered question, 
with a number of other related questions including; the importance of central nervous system 
penetrance of the conditioning regimen chemotherapeutic agents and the level of 
chemotherapeutic drug concentration within the brain that can lead to the clearance of 
pathological immune cells. These questions need to be addressed with an appropriate 
randomised study to identify the regimen with the best risk: benefit ratio.  
Text box 1 highlights the different stages of an AHCT. 
2.2 Mechanism of action 
The exact mechanism by which AHCT stops disease activity in MS is yet to be fully 
established. By using a high dose of chemotherapy, a large proportion of the white cells, 
including pro-inflammatory cells, are destroyed in both blood and bone marrow, which may 
H[SODLQWKHHDUO\LPSURYHPHQWLQSDWLHQWV¶FRQGLWLRQ 
Evidence for resetting of the immune system through T-cell receptor diversification, 
elimination of memory cells and thymic dependent generation of naïve and T-regulatory cells 
may explain the longer term effects of the AHCT on disease suppression [9]. AHCT does 
lead to the suppression of production of certain types of T-cell  [22;23] but the balance 
between regulatory and pro-inflammatory lymphocytes is re-set in favour of regulatory cells 
[24]. 
Following AHCT patients have a greater diversity of naïve T-cells with reduction in memory 
cells [25] which may contribute to the development of immune tolerance [26].  These new T-
cells are generated in the thymus, which goes through a period of increased activity after the 
AHCT [25].  This increased thymic activity contrasts with the reduced activity noted in 
untreated MS patients, and it is assumed that AHCT corrects this deficiency [27]. When 
patients fail to develop a diverse repertoire of naïve T-cells post-transplant, their response to 
treatment is likely to be less successful [28]. Figure 2 summaries the possible mechanisms 
underlying AHCT in MS.  
 
2.3 Comparing AHCT to alternative disease modifying treatments (DMTs) 
Only a handful of trials have directly compared the use of AHCT in MS with specific disease 
modifying therapies. The bulk of data are provided by observational cohort studies in which 
patients who fail to respond to standard disease modifying therapies are treated with AHCT. 
The observational nature of these studies has to be taken into account when interpreting the 
results. Tables 2 and 3 summarise relapse free survival and NEDA in different AHCT and 
DMT trials respectively. NEDA figures were not collected in the original DMT clinical trial 
studies, but subsequently calculated mainly by Sormani et al [29]. 
 An international randomised controlled trial is being conducted to compare AHCT with 
other FDA approved DMT¶V (MIST Study [ClinicalTrials.gov Identifier: NCT00273364]) 
and is anticipated to provide further evidence on the efficacy of ACHT in MS   
2.3.1 Interferon Beta and Glatiramer acetate 
Interferon beta has multiple methods of action, including inhibiting leukocytes trisecting into 
the brain, modulating cytokine production and potentially inhibiting antigen presentation 
which results in its therapeutic effect in MS [30]. When compared with placebo, interferon 
beta has been shown to increase the time between relapses by between 3-5 months and 
decreases the risk of further relapse by 27-33% [31].  
Glatiramer acetate, a modulator of T-cell differentiation [32] has a similar effect on relapse 
rate, but does not control MRI gadolinium enhancement in the early stages of treatment as 
well as interferon beta [33].  
Although no study has looked specifically at how there two agents compare to AHCT, a 
grouped analysis from the EBMT showed that in patients who developed relapses whilst on a 
DMT (the vast majority of which were either on interferon or glatiramer acetate) disease 
improvement or stabilisation could be achieved in 63% of patients at a median of 41.7 
months post-transplant [16]. 
2.3.2 Natalizumab  
Natalizumab is a humanised monoclonal antibody that targets the Į-VXEXQLWRIĮȕ-
integrin, an adhesion molecule found on all leukocytes except neutrophils [34]. It works by 
preventing the migration of lymphocytes across the blood brain barrier. The two main 
randomised control trials for natalizumab (AFFIRM and SENTINEL) showed that it is very 
effective in reducing annualised relapse rate (0.81 to 0.26 in AFFIRM and 0.75 to 0.34 in 
SENTINEL). [34;35].  
Initial trial data have been corroborated with follow up studies showing that natalizumab has 
sustained effects on reduction of relapse rate and progression of disability as measured by the 
EDSS for at least 2 years [36]. Over time, patients continue to experience progression of 
disability, albeit at a slower rate than prior to treatment.  
The use of natalizumab has been associated with the JC-virus induced progressive multifocal 
leukoencephalopathy (PML). A recent report suggested that the prevalence of PML in 
patients treated with natalizumab is 2.1/1000 patients [37]. The risk factors for developing 
PML include the use of prior immunosuppressive drugs, the use of natalizumab for greater 
that 2 years and being JC-virus positive [37]. High levels of JC Antibody Index (1.5) are 
associated with the risk of PML as high as 1 in 263 patients [38]. 
No study as yet has compared AHCT directly with natalizumab. One study has looked at the 
efficacy of AHCT in patients with RRMS who have continued to have relapses whilst treated 
with disease modifying therapies, including natalizumab [23]. This study showed that at 3 
years, the event free survival in patients treated with AHCT was 78.4% which is higher than 
that reported in the AFFIRM study for natalizumab. A large North American cohort study of 
145 patients (123 RRMS and 28 SPMS), who failed standard disease modifying therapies 
including natalizumab, found the 4-year relapse free survival rate with AHCT to be 80% and 
NEDA rate to be 68% [39]. A Swedish study of 48 patients (34 RRMS) who had aggressive 
disease and had failed conventional treatment, including natalizumab, found the relapse free 
survival rate to be 87% and a NEDA rate of 68% also [40].  The high NEDA rates seen in 
patients treated with AHCT is even more impressive when we consider that such patients 
generally have more active disease than those patients treated in trials for the other types of 
DMTs [41]. 
PML and JC virus infection are unlikely to be a long-term problem in AHCT treatment, as 
after the initial reconstitution of the immune system in AHCT, patients are not 
immunosuppressed unlike when they are treated with natalizumab. PML secondary to JC-
Virus infection could theoretically be a problem in AHCT if the patient undergoing the 
treatment is a carrier of the JC-virus prior to the transplant. No study has reported infection 
with JC-Virus after AHCT currently. 
2.3.3 Alemtuzumab  
Alemtuzumab is a humanised anti-CD52 monoclonal antibody that depletes both B and T-
lymphocytes changing a person adaptive immunity. Most studies assessing the efficacy of 
this drug compare the drug to interferon beta. In the CARE-MS-I trial, alemtuzumab was 
compared to interferon beta in patients with RRMS who had not previously had any disease 
modifying therapy for their MS [42]. At 2, years 78% of patients where relapse-free 
(interferon group 59%). NEDA rate were 39%.  In the CARE-MS-II study patients were 
deemed suitable for trial entry when they had a relapse on interferon-beta [43]. At 2 years, 
66% of patients were relapse free when compared to patients who had remained on 
interferon-beta. NEDA rates in this study were 32%. This is significantly less than the relapse 
free rate of patients who have been treated with AHCT as highlighted above. 
The main concern of using alemtuzumab is the development of autoimmune complications. 
One follow up study reported that 33% of patients developed autoimmune thyroid problems, 
2.8% of patients developed immune thrombocytopenia and 0.46% developed anti-GBM 
antibodies after five years of follow up [44].  The development of anti-GBM antibodies is of 
SDUWLFXODUFRQFHUQDVWKHYDVFXOLWLVFDXVHGE\WKHVHDQWLERGLHV*RRGSDVWXUH¶V6\QGURPHFDQ
lead to death in a significant number of cases. The main risk of developing a thyroid problem 
is within the first 3 years of drug initiation, the risk reducing after that. 
Alemtuzumab has been incorporated as the T-cell depleting serotherapy in the conditioning 
regimen in some studies of AHCT in MS [13], but this was associated with an apparent 
increased risk of secondary autoimmune diseases compared with the use of rabbit anti-
thymocyte globulin (rATG) in this context. Caution and further studies are warranted to fully 
assess the utility of alemtuzumab in the conditioning regimen but for the present time rATG 
continues to be the preferred serotherapy for the AHCT procedure.   
2.3.4 Mitoxantrone 
Mitoxantrone is a cytotoxic agent which works by stopping DNA repair through inhibiting 
topoisomerase activity. The drug has been shown to be useful in treating both RRMS and 
SPMS [45]. It is now very rarely used in MS therapy though due to concerns over its toxic 
side effects. 
An early trial on AHCT compared Mitoxantrone to AHCT in patients with both RRMS and 
SPMS [46] had to be terminated due to poor recruitment. Although not powered to look for a 
difference in relapse rates in patients with RRMS or disease progression, it did show that the 
number of gadolinium enhanced lesions in the brain of people with both SPMS and RRMS 
reduced significantly when comparing AHCT with Mitoxantrone.  
2.3.5 Other Disease modifying agents 
Limited specific data exist on how other disease modifying agents such as fingolimod and 
dimethyl fumarate compare to AHCT.  Patients on these therapies have been treated with 
AHCT and included in some of the trials mentioned above. The control arm in the on-going 
MIST trial allows for patients to be treated with fingolimod or dimethyl fumarate.   
2.3.6 Alternative Cell therapies  
Other cell therapies similar to AHCT are also currently being developed to treat MS and 
other autoimmune diseases. One such therapy is mesenchymal stem (or stromal) cell (MSC) 
transplantation. This particular type of transplantation uses non-hematopoietic precursor 
cells, which can differentiate into mesodermal cell derivatives, but, perhaps more 
significantly, have immunomodulatory properties. Both autologous and allogeneic (third 
party donor, cord blood and placental) derived MSC have been studied as 
immunomodulatory treatments, although the place of MSC in autoimmune diseases, 
including MS remains to be clarified  [47]. 
Allogeneic hematopoietic cell transplantation has also been used in MS patients, mainly those 
with another diagnosis which formed the main indication for the transplant [48]. Given that 
allogeneic transplantation results in replacement of an aberrant immune system, it appears to 
be effective in halting disease activity and potentially progression of autoimmune diseases. 
However, the substantial additional risks, including graft- versus-host disease and a 
substantial TRM risk, could rarely, if ever, be justified in MS. 
 
2.4 Which MS patients should be offered AHCT 
A review of a cohort of 151 patients showed that the use of AHCT was associated with an 
improvement of the EDSS scored in patients with RRMS who had the disease for 10 years or 
less compared to those with SPMS and a longer disease duration [39].  A small cohort study 
in the Czech Republic (n=26) found that AHCT has a more favourable outcome in patients 
who are not older than 35 years and have had the disease for less than 5 years [49]. Although 
the follow up period in this study was long (median 7 years), only a small number of patients 
where under the age of 35 (n=6).   
Evidence of gadolinium enhancement on MRI prior to transplant is associated with a more 
favourable outcome [15;40]. Although AHCT is not normally offered to patients with 
significant long term fixed disabilities, EDSS score prior to AHCT treatment was reported 
not to be a good predictor of outcome [49]. This is thought to be the case for the number of 
DMTs used before AHCT [39].  
It is known that MS has variable prevalence rates in different ethnic groups [50] although 
cohort studies from China have shown that AHCT has a similar effect on the disease when 
compared with studies done on North American and European populations [51].  
Currently, HSCT is thought to be most effective in patients with RRMS who are 46 years or  
younger, have had the illness for less than 10 years and who have active disease clinically 
with evidence of enhancement on their MRI (See Table 4).  
Various selection biases are inherent in published AHCT studies as a treatment for MS. 
Historically, the use of AHCT was reserved for younger patients with aggressive and 
potentially end stage disease where other treatments had failed. However with increasing 
experience, AHCT has been used earlier in the course of MS. Published studies are likely to 
be biased towards younger age groups owing to the fact that such patients have the  high level 
of general fitness needed for AHCT, and because relapsing remitting MS is very unlikely to 
present in older cohorts of patients. Further studies, including randomised controlled trials, 
are warranted to overcome such bias and inform decision making for patients at all ages and 
stages of MS. Reduced intensity conditioning regimens may be more appropriate for older 
and less fit patients. 
2.5 Early and late complications of AHCT for MS 
AHCT has intrinsic risks related to the toxicity of the high-dose conditioning treatment 
regimens and the temporary but profound cytopenia lasting for 1-2 weeks. Although some 
series have reported no treatment related mortality, retrospective multi-centre EBMT studies 
have been associated with a 100-day mortality of 1.3% [52] and high-intensity BuCy regimen 
used by Canadian investigators was associated with higher levels of toxicity [20].  Therefore, 
AHCT should be reserved for patients who have very active disease which has failed to 
respond to standard DMTs. With the exception of urinary tract infections, patients with MS 
seem to have similar complication rates during the acute treatment phase compared to 
patients with other hematopoietic and autoimmune diseases treated with AHCT [10;53].  
Fever associated with ATG and post-transplant infection can exacerbate patients neurological 
symptoms during the early stages post-transplant [53;54]. This is thought to be secondary to 
conduction block in demyelinated neurones caused by the increased temperature. Non-
infective pyrexia (temperature greater than 38.5oC) has also been shown to be associated with 
less favourable neurological outcomes post-AHCT. For this reason, steroids and paracetamol 
may be used after transplant to prevent or treat pyrexia, along with appropriate assessment 
and treatment of potential infections. Limiting fever during the per-transplant phase may help 
prevent or resolve this  Uthoff-like phenomenon, in the short term and there may be longer 
term benefits, which need to be confirmed [39]. 
Following AHCT some patients develop autoimmune hyper and hypothyroidism and 
thrombocytopenic purpura [13;39]. The rate of such autoimmune complications were higher 
when alemtuzumab (22.7%) rather than ATG (6.9%) was used in the conditioning regimen.  
Secondary malignancy post-transplant has been reported following AHCT. In a cohort study 
of 151 patients underwent AHCT, one patient developed breast cancer and another developed 
lymphoma [39]. However, secondary malignancy appears to be rare following AHCT and 
MS patients who are managed with DMTs have an excess of malignancy. For example, two 
cases of papillary thyroid cancers were reported in the CARE-MS-1 study, giving a rate of 
1% [42]. In the CARE-MS-II study 5 (1.3%) people developed malignancy in the 
alemtuzumab group compared to 2 (1%) in the interferon group [43].  
Vigilance should be maintained post AHCT. A case of Epstein-Barr Virus related post-
transplant lymphoproliferative disorder (EBV-PTLD) has been reported as the cause of death 
in one patient who received rATG in their conditioning regimen [10].  
Herpes zoster is probably the commonest late infection post- AHCT in MS [40] and patients 
are often advised to stay on prophylactic acyclovir for at least a year post-transplant.  
Gonadal failure and infertility need to be considered when counselling patients for AHCT. 
Patients should be offered cryopreservation of their ova/sperm prior to the procedure. Limited 
data about fertility post-AHCT are available. A cohort study of 48 patients (26 females) with 
MS reported a total of 8 pregnancies after treatment [40]. A total of 5 healthy infants were 
born whereas 2 pregnancies ended in miscarriage and one was ectopic. Of the patients who 
had their ova/sperm cryopreserved both a male (n=1) and female (n=1) were able to produce 
a child.  
Limited data are available on other long-term outcomes of AHCT in MS. The use of AHCT 
in other diseases is associated with cardiovascular, endocrine and musculoskeletal 
complications [55].  The risk of such complication in MS needs to be viewed in the light of 
the fact that in some of the rapidly progressive forms of MS, in which AHCT appears 
particularly effective, life expectancy can be in the order of weeks to months and associated 
with marked disability [56].  
It is important that the transplant and neurology community continue to report the long-term 
outcomes of these patients so the late effects of AHCT can be fully evaluated in the MS 
population. The EBMT data registry and similar organisation provide a means of long term 
follow-up of both efficacy and late complications. Table 5 highlights some common 
complications reported in AHCT. 
2.6 Future of AHCT in MS 
As AHCT becoming a more mainstream therapy in the treatment of MS, certain questions 
remain unanswered. Compared with other DMTs, the risks of early mortality and morbidity 
from AHCT is relatively high, although this appears to have improved significantly over the 
last ten years, due to the use of safer conditioning regimens, better patient selection and 
increasing experience [39;40]  
Although AHCT as a one-off treatment is likely to be more cost-effective than modern DMTs 
used, this will be need to be addressed prospectively in future studies [57].  
Whether AHCT can cure MS remains to be seen. This treatment appears to be able to 
completely prevent recurrence of clinical relapses and MRI disease activity [20], halt disease 
progression and improve disability scores in a significant number of patients [39]. 
Improvement in NEDA rates seen with the use of AHCT when compared to other disease 
modifying therapies is striking (see table 2 and 3).  Long term follow up will be necessary to 
assess whether AHCT can cure in some patients. 
3.0 Conclusions 
AHCT has been used for the treatment of MS for over two decades. Cohort and small 
randomised studies showed that patients with RRMS form of MS have a better response and 
increasing experience has enabled safer delivery of this approach. Further long term follow 
up is needed before the benefits and safety of AHCT can be fully assessed. The use of AHCT 
in MS is not without risk and patients must be carefully selected. AHCT needs to be further 
refined and compared with the current standard of care for patients with RRMS in large 
randomised trials.   
4.0 Expert Opinion 
Although Autologous Hematopoietic Cell Transplantation (AHCT) has been used to treat MS 
since 1995, recent evidence from published case series and phase II clinical trials supports 
AHCT as an effective treatment for patients with highly active RRMS resistant to Disease 
Modifying Therapies. AHCT reduces clinical relapse rates, MRI disease activity and the 
progression of disability. In some patients, AHCT even reverses the disability caused by this 
illness. The best results are observed in young patients with short disease duration who have 
very active disease clinically and radiologically. AHCT has limited or no effect in patients in 
patients with progressive forms of MS. 
 AHCT is an intensive procedure involving high-dose chemotherapy and serotherapy with 
their inherent toxicities and should only be delivered in accredited centres where there is 
close working between transplant haematologists and MS specialist neurologists.  In 
experienced transplant centres the treatment-related risks have been minimised and are now 
considered justified in well-selected and motivated patients with highly active, treatment 
resistant RRMS, who would otherwise have a poor prognosis. 
 Centres should follow international guidelines, such as those from the European Society for 
Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP), 
which provide recommendations for patient selection and regimens for stem cell 
mobilisation, transplantation and supportive care. Data reporting to the EBMT or other 
transplant registries is a mandatory requirement. 
 Further data are needed to assess the long-term safety and efficacy of AHCT. The future 
place of AHCT in the MS treatment algorithm will need to be evaluated in the light of the 
outcome of the ongoing phase III MIST trial but it is likely to be an attractive and cost-
effective second line therapeutic option for patients who have active RRMS who have failed 
a first line DMT. Even after MIST, further trials will be necessary to optimise the transplant 
regimen and compare AHCT against new DMTs.  
 Destroying and rebuilding the abnormal immune system with AHCT will help improve our 
understanding of the role of the innate and adoptive immune systems in the pathogenesis of 
MS and has the potential to radically change the way in which treatment for MS is provided. 
The evolving translational approach to research in this field, combined with further 
therapeutic developments in the delivery of AHCT, have the potential to turn MS into a 
curable disease which no longer comes with a sentence of long term disability. 
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Figure Legends 
 
Figure 1: This figure highlights the new classification structure for MS used in clinical trials 
as suggested by Lublin et al 2014 [3]. * Active disease refers to the presence of a relapse or 
measureable active disease on MRI imaging. ** Progression refers to a sustained change in 
the patients EDSS over a set time period, often longer than 6 months. 
Figure 2: This figure highlights the possible biochemical changes to the immune system that 
may explain why AHCT halts MS. 
 
 
EDSS Score  
0.0 Normal neurological exam 
1.0 No disability, minimal signs in more than one FS 
 Table 1: The Kurtzke Expanded Disability Status Scale (EDSS) this scale is often used in 
MS research to monitor progression of the disease. FS stands for functional status. The 
overall EDSS score is calculated from different parts or the neurological exam. Each of these 
give a FS which is then used to calculate the EDSS. 
1.5 Minimal disability in one FS 
2.0 Minimal disability in two FS 
2.5 Moderate disability in one FS (one FS grade 3, others 0 or 1) or mild 
disability in three or four FS (three or four FS grade 2, others 0 or 1) 
though fully ambulatory. 
3.0 Fully ambulatory but with moderate disability in one FS (one grade 3) and 
one or two FS grade 2; or two FS grade 3 (others 0 or 1) or five grade 2 
(others 0 or 1). 
3.5 Fully ambulatory but with moderate disability in one FS (one grade 3) and 
one or two FS grade 2; or two FS grade 3 (others 0 or 1) or five grade 2 
(others 0 or 1).  
4.0 Fully ambulatory without aid, self-sufficient, up and about some 12 hours 
a day despite relatively severe disability consisting of one FS grade 4 
(others 0 or 1), or combination of lesser grades exceeding limits of 
previous steps; able to walk without aid or rest some 500 meters.   
4.5 Fully ambulatory without aid, up and about much of the day, able to work 
a full day, may otherwise have some limitation of full activity or require 
minimal assistance; able to walk without aid or rest some 300 meters.   
5.0 Ambulatory without aid or rest for about 200 meters; disability severe 
enough to impair full daily activities (e.g., to work a full day without 
special provisions);  
5.5 Ambulatory without aid for about 100 meters; disability severe enough to 
preclude full daily activities 
6.0 Intermittent or unilateral constant assistance (cane, crutch, brace) required 
to walk about 100 meters with or without resting 
6.5 Constant bilateral assistance (canes, crutches, braces) required to walk 
about 20 meters  without resting; 
7.0 Unable to walk beyond approximately 5 meters even with aid, essentially 
restricted to wheelchair; wheels self in standard wheelchair and transfers 
alone; up and about in wheelchair some 12 hours a day. 
7.5 Unable to take more than a few steps; restricted to wheelchair; may need 
aid in transfer; wheels self but cannot carry on in standard wheelchair a 
full day 
8.0 Essentially restricted to bed or chair or perambulated in wheelchair, but 
may be out of bed itself much of the day; retains many self-care 
functions; generally has effective use of arms. 
8.5 Essentially restricted to bed much of day; has some effective use of 
arm(s); retains some self-care functions 
9.0 Helpless bed patient; can communicate and eat 
9.5 Totally helpless bed patient; unable to communicate effectively or 
eat/swallow 
10.0 Death due to MS 
Text Box 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BOX 1: PHASES OF THE AHSCT PROCEDURE 
1. Mobilisation and harvest.  In the first stage the patient is given a short course of granulocyte-
colony stimulating factor (G-CSF) which releases hematopoietic stem cells into the peripheral 
circulation. Most centres performing this step will supplement the G-CSF infusion with 
chemotherapy, often cyclophosphamide 2-4g/m2, which not only mobilises the stem cells for 
harvest by apheresis but also provides some interim suppression of disease activity.  
2. Conditioning and stem cell re-infusion. In this stage the patient is given a high dose of 
cytotoxic therapy (i.e. chemotherapy, radiotherapy and/or serotherapy, such as ATG or 
monoclonal antibodies such as alemtuzumab) to eliminate the majority, if not all, of their bone 
marrow and immune system. Conditioning regimens can be of differing intensities, as described 
above. 
3. Following conditioning, the stem cells collected in the mobilisation stage are re-infused into 
the patient.  Engraftment is confirmed when the patient starts producing peripheral blood cells 
again. 
  
Table 2: Shows outcomes from various cohort studies and trials performed concerning MS 
patients who have undergone AHCT. NCG means No Comparator Group as this was a cohort 
study. ** In the Burman 2014 study 8 patients where included that did not have RRMS and 
instead had a diagnosis of SPMS. %XUWLVDIROORZXSVWXG\WKDWXVHVWKHVDPHSDWLHQWV
that are in Burt 2009, but with increased recruitment.  
 
Table 3: LQGLFDWHVWKDWWKHGDWDZDVQRWGLVSOD\HGUHIHUVWRSDWLHQWVWDNLQJPJRI
Fingolimod. 
 
 
 
 
Study Number 
of 
Patients 
Relapse Free 
survival at 
one year 
New Gad 
positive MRI 
Lesions at 1 
year 
EDSS 
change at 
one year 
median 
NEDA (No 
evidence of 
disease 
activity) 
Conditioning Regimen Justification for 
AHCT 
Notes 
Burman 
2014 
48 87% at 5 
years 
8 new lesions in 
entire cohort 
during all follow 
up 
-0.75 (All 
patients) 
-1.5 
(Progressive 
patients 
excluded) 
68% at 5 years BEAM/ATG (n=41) 
 
Cyclophosphamide 
/ATG (n=7) 
Patients treated as 
rescue therapy for 
severe RRMS** 
Cohort study 
based on 
responses to a 
survey 
HALT-MS 
Nash 2015 
24 86.3% at 3 
years 
0 at 3 years 2 
patients 
developed lesion 
thereafter 
-0.5 at 3 
years 
78.4% at 3 
years 
BEAM/ATG failure of DMT (2 
or more clinical 
relapses during past 
18 months  
associated with 
increased EDSS 
score. 
Single arm 
phase 2 
clinical trail 
(HALT-MS) 
Burt 2009 21 62% at 3 
years 
5 patients by end 
of follow up (3 
years) 
-0.9 at 1 
year and -
1.7 at 4 
years 
62% at 3 years Cyclophosphmide/Mesa/ 
Alemtuzumab/ 
Methylprednisolone 
interferon beta 
treatment plus 
corticosteroid-
treated relapses last 
12 months, or 1 
relapse and 
gadolinium-
enhancing lesions 
seen on MRI. 
Prospective 
Cohort Study 
Burt 2015 145 89% at 2 
years and 
80% at 4 
years 
* -1.0 at 1 
year and -
1.5 at 5 
years 
68% at 4 years Cyclophosphomide plus 
with Alemtuzumab or 
ATG.  
interferon beta 
treatment plus 
corticosteroid-
treated relapses last 
12 months, or 1 
relapse and 
Observational 
Cohort Study 
gadolinium-
enhancing lesions 
seen on MRI. 
Shechenko 
2008  
45 * None in patients 
who did not have  
relapse 
28 patients 
had a drop 
of EDSS of 
0.5 at 6 
months 
* BEAM/ATG Confirmed 
diagnosis of MS 
with an EDSS 
between 1.5-8.0. 
Prospective 
Cohort Study 
Study Number 
of 
Patients 
Relapse Free 
survival at one 
year 
New Gad positive 
MRI Lesions at 1 
year 
EDSS change 
at one year 
median 
NEDA (No 
evidence of 
disease activity) 
Notes 
AFFIRM  
Polman 2006 
627 68% reduction 
in relapse rate 
compared to 
placebo 
245 patients had at 
least one new 
lesion 
* 37% at 2 years Randomised control 
trial 
CARE-MS-1 Cohen 
2012 
386 77.6% at 2 
years 
176 patient had 
new of enlarging 
lesions at 2 years 
-0.14 at 2 
years 
39% at 2 years Randomised control 
trial 
CARE-MS-II Coles 
2012 
436 65% at 2 years 186 patient had 
new lesions at 2 
years 
-0.17 at 2 
years 
32% at 2 years Randomised control 
trial 
FREEDOM 
Kappos 2010 
854 60% in relapse 
rate compared 
WRSODFHER 
35 patients had new 
OHVLRQVDW\HDUV 
-0.03 at 2 
\HDUV 
48% at 2 years Randomised control 
trial 
  
Table 4: factors that are associated with a more favourable outcome after AHCT in MS. 
 
 
 
 
 
Favourable outcome for AHCT in MS is seen in 
x RRMS  
x Young patients (<_45 years) 
x Short disease duration (<_10 years)  
x Active disease (two or more relapses in 12 months in the preceding 12 months) 
x Evidence of Gadolinium enhancement on MRI scans 
 
  
 
Table 5: This table shows the common side effects reported in each of the main AHCT studies 
post transplant. * indicates that this information was not in this particular study. 
 
Study Number of Deaths 
secondary to AHCT 
Infection Rate Other complications Mean Length 
of Follow up 
Burman 2014 No Deaths 17 Neutropenic 
fever 
8 Herpes Zoster 
Infections 
3 Clostridium 
Difficile 
1 Candida  
 
4 Hypothyroid disease  
&URKQ¶V'LVHDVH 
1 Alopecia  areata 
1 Incontractable Epilepsy 
1 Deep Vein Thrombosis 
47.4 months 
HALT-MS 
Nash 2015 
2 Deaths one secondary 
to asthma and one 
secondary to MS 
progression 
16 Neutropenic 
fevers 
1Clostridium 
Difficile 
3 Deep Vein thrombosis 
1 Pulmonary Embolism 
46.5 Months 
(Median) 
Burt 2009 No Deaths 
5 neutropenic fevers 
2 Zoster infections 
1Clostridium 
Difficile 
2 Immune 
thrombocytopenia 
37 Months 
Burt 2015 No Deaths 4 Clostridium 
Difficile 
7 Immune 
thrombocytopenia 
7 Thyroid disease 
30 Months 
Shechenko 
2008  
1 death due to 
intracranial haemorrhage 
* * 19 Months 
  
 
Article Highlights; 
x Originally supported by animal models and serendipitous case reports, AHSCT has been used 
in multiple sclerosis since 1995. AHSCT is an intensive procedure involving high-dose 
chemotherapy and serotherapy with their intrinsic risks. 
 
x Although it has a limited effect on progressive forms of multiple sclerosis, in relapsing 
remitting multiple sclerosis AHSCT appears to reduce clinical relapses and MRI disease 
activity and halt the progression of disability. NEDA rates after treatment with AHSCT appear 
to much higher than any other MS disease modifying therapy, although randomised 
controlled trial data is awaited. 
 
x AHSCT appears to work through an immediate debulking of neuro-inflammation followed by 
longer-term modulation of the immune system, with re-diversification and renewal of T cell 
populations, including T-regulatory cells. 
 
x Further work needs to focus around the long term effects of use of AHSCT in MS. 
 
